Publication: Effects of pharmacist interventions on cardiovascular risk factors and outcomes: An umbrella review of meta-analysis of randomized controlled trials
| dc.contributor.author | Rattanavipanon W. | |
| dc.contributor.author | Chaiyasothi T. | |
| dc.contributor.author | Puchsaka P. | |
| dc.contributor.author | Mungkornkaew R. | |
| dc.contributor.author | Nathisuwan S. | |
| dc.contributor.author | Veettil S.K. | |
| dc.contributor.author | Chaiyakunapruk N. | |
| dc.date.accessioned | 2022-12-14T03:16:56Z | |
| dc.date.available | 2022-12-14T03:16:56Z | |
| dc.date.issued | 2022 | |
| dc.date.issuedBE | 2565 | |
| dc.description.abstract | Aims: To grade the evidence from published meta-analyses of randomized controlled trials (RCTs) that assessed effects of pharmacist intervention on cardiovascular risk factors and cardiovascular outcomes. Methods: MEDLINE, Embase, and the Cochrane Library were searched from database inception to July 2021. Meta-analyses of RCTs were eligible. Quality of evidence were assessed by GRADE approach. Results: From 9308 publications, 149 full-text articles were evaluated for eligibility, and 24 studies with 85 unique meta-analyses that assessed effects of pharmacist intervention on cardiovascular risk factors and cardiovascular outcomes were selected. Overall, 71.7% (61/85) of unique meta-analyses showed significant impacts of pharmacist intervention. For the quality of evidence, 63.4% of meta-analyses had large heterogeneity (I2 > 50%) while 1.2, 16.5, 32.9 and 49.4% of meta-analyses were graded as high, moderate, low and very low quality based on GRADE approach, respectively. Among meta-analyses with moderate quality, pharmacist interventions significantly mitigated risk factors (including 6/3 mmHg reduction of blood pressure, increased the rate of lipid control, glucose control and smoking cessation (pooled odds ratio, [95% confidence interval] 1.91 [1.55, 2.35], 3.11 [2.3, 4.3] and 2.3 [1.33, 3.97], respectively) and improved medication adherence (1.67 [1.38, 2.02]). Furthermore, pharmacist interventions significantly reduced all-cause mortality (0.72 [0.58, 0.89]) and improved quality of life in patients suffering from chronic heart failure. Conclusion: This umbrella review found convincing evidence that pharmacist intervention can provide a wide range of benefits in cardiovascular disease management, ranging from risk factor control, improvement in medication adherence and, in some settings, reduction in morbidity and mortality. © 2022 British Pharmacological Society. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.citation | Clinical Ophthalmology. Vol 16, No. (2022), p.1871-1882 | |
| dc.identifier.doi | 10.1111/bcp.15279 | |
| dc.identifier.issn | 3065251 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14740/9216 | |
| dc.language.iso | eng | |
| dc.publisher | John Wiley and Sons Inc | |
| dc.rights.holder | Scopus | |
| dc.subject.other | Cardiovascular disease | |
| dc.subject.other | Intervention | |
| dc.subject.other | Meta-analysis | |
| dc.subject.other | Pharmacist | |
| dc.subject.other | Umbrella review | |
| dc.title | Effects of pharmacist interventions on cardiovascular risk factors and outcomes: An umbrella review of meta-analysis of randomized controlled trials | |
| dc.type | Other | |
| dspace.entity.type | Publication | |
| swu.datasource.scopus | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125997780&doi=10.1111%2fbcp.15279&partnerID=40&md5=f16c6cf1d00aae9f3285417e468a5641 |
